Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
A Multicentre Phase III Randomized Double Blind Placebo Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Patients With Small Lung Cancer
Sponsor: University College, London
A PHASE3 clinical study on Lung Cancer, this trial is completed. The trial is conducted by University College, London and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jan 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University College, London
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom , Ashford-Kent, United Kingdom , Aylesbury-Buckinghamshire, United Kingdom , Barnstaple, United Kingdom , Bath, United Kingdom , Birmingham, United Kingdom , Bournemouth, United Kingdom , Bradford, United Kingdom , Brighton, United Kingdom , Burton-on-Trent, United Kingdom and 66 more locations